Previous 10 | Next 10 |
Introduction Through Week 26 of 2020, the Premium Portfolio has gained +14.43%, substantially leading the S&P 500 benchmark by +21.29%. These returns were achieved by actively trading in 11 fewer weeks (nearly halted for an entire quarter) using the alerts of the Momentum Gauge™ t...
Meridian Bioscience (NASDAQ: VIVO) ran past its 52-week high last week, closing on Monday at $19.69. The diagnostic testing company, which has thrived during the COVID-19 pandemic, had record revenue in the first quarter. The question is, is it time to get out and take profits yet? The shor...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 162 weeks of public selections as part of this ongoing live forward-testing re...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 160 weeks of public selections as part of this ongoing live forward-testing resea...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 160 weeks of public selections as part of this ongoing live forward-testing resea...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 159 weeks of public selections as part of this ongoing live forward-testing resea...
CINCINNATI, May 29, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the 40 th Annual William...
CINCINNATI, May 26, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that its SARS-CoV-2 antigens and related reagents are part of assays granted U.S. Food and Drug Administr...
CINCINNATI, May 20, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc.’s (NASDAQ: VIVO) Board of Directors announced that Tony Serafini-Lamanna has been promoted to Executive Vice President of Diagnostics. Jack Kenny remains Chief Executive Officer of Meridian, while passing re...
Image source: The Motley Fool. Meridian Bioscience Inc (NASDAQ: VIVO) Q2 2020 Earnings Call May 9, 2020 , 9:00 p.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Meridian Bioscience Inc. Company Name:
VIVO Stock Symbol:
NASDAQ Market:
Meridian Bioscience Inc. Website:
Net revenue for Q4 2022 was $7.1 million, a 15% increase from prior quarter. Net revenue for 2022 was $25.4 million, a 2% increase compared to 2021. Net losses have decreased by 21.2 million in 2022, a 30% decrease from the prior year. The Company signed a definitive agreemen...
Toronto, Ontario--(Newsfile Corp. - March 24, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that it has obtained a final court order (the " Final Order ") from the Ontario Superior Court of Justice (Commercial List) approving the previously announced pl...
Toronto, Ontario--(Newsfile Corp. - March 21, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that, at the special meeting of the shareholders of VIVO (the " Shareholders ") held today (the " Meeting "), the Shareholders approved (i) a special resolutio...